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Introduction
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, and lethal fibrotic lung disease [1] . IPF is characterized by alveolar epithelial cell injury and activation, the formation of myofibroblast foci, and the exaggerated accumulation of extracellular matrix in the lung parenchyma. Despite significant progress, the etiology and molecular mechanisms underlying IPF are largely unknown [2] .
MicroRNAs (miRNAs) constitute a large family of regulatory RNAs that inhibit 3 of 25 target expression by base pairing with complementary sites in the 3′ untranslated region (3′ UTR) to promote mRNA decay and translational repression [3] .The critical roles of miRNAs in development and that their dysregulation causes diseases have been increasingly known [4] . Therefore, identifying disease-specific miRNAs can reveal novel mRNA target pathways and provide insight into the pathogenesis of specific diseases and therapeutic targets [5] . Recent research reported that circulating miRNAs are very stable in plasma and serum and remain stable when free from RNases under conditions of long-term storage or repeated freezing and thawing; these features show that the circulation miRNAs from patients can be used as a biomarker for diagnosis and treatment [6] [7] [8] . However, the mechanisms of circulating miRNAs controlling the IPF progression remain poorly understood.
Oxidative stress is an important phenomenon in the pathological processes of IPF and is commonly associated with the oxidative damage of epithelial cells, which is believed to be the initial event that triggers a series of aberrant repair pathways that lead to inappropriate fibrosis [9] . Du Bois once proposed that targeting the manipulation apoptosis of epithelial cell appears to be an advantageous approach to treating IPF. Considering novel antioxidant approaches is also recommended [10] . Therefore, our study focused on miR-30a regulation on the epithelial cell apoptosis during H2O2-induced IPF. Pandit et al. reported that the miR-30 family significantly decreased in IPF patients [11] . However, the regulation mechanism of miR-30 in IPF has never been systematically explored until now. Our previous study demonstrated that miR-30a may function as a novel therapeutic target for lung fibrosis by blocking 4 of 25 mitochondrial fission, which is dependent on dynamin-related protein-1 (Drp-1) [12] .
However, three critical issues must be addressed. First, the expression of miR-30a in IPF patients has not been evaluated. Second, the target gene of miR-30a and the regulatory mode between the target gene and Drp-1 has yet to be investigated. Third, whether miR-30a can act as a potential therapeutic has not been verified in vivo. In this study, we further evaluated the circulating miR-30a expression in IPF patients and explored the miR-30a target gene of methylcytosine dioxygenase ten-eleven translocation 1 (TET1) and the regulatory mode between TET1 and Drp-1. Finally, we designed and applied the miR-30a agomir to identify and validate the therapeutic effect of miR-30a in vivo.
Results

miRNA-30a expression in patients and analysis of the possible target gene
Our previous study reported that miR-30a decreases in the in vivo and in vitro models of lung fibrosis [12] . In this study, we further evaluated the miR-30a expression in IPF patients to assess the significance of miR-30a in clinical research.
The qRT-PCR result shows that the level of circulating miR-30a expression decreases in IPF patients compared with the normal level. This result is in agreement with that of our previous work with in vivo and in vitro models. miRNAs exert their regulatory functions through specific interactions with their target genes. Therefore, the target genes of miR-30a were first predicted based on TargetScan, miRanda data, and miRbase. The computational analysis data showed that binding sites with miR-30a may exist in the 3′UTR of TET1 and TET3. Thus, that miR-30a is inversely correlated with TET1. Therefore, only TET1 was selected as miR-30a target for further study.
Confirmation of TET1 as a target gene of miR-30a
To verify TET1 as a target gene of miR-30a, we set up a dual luciferase assay reporter system by amplifying and inserting the 3′ UTR of TET1 into the pMIR-REPORT vector, which contained downstream firefly luciferase. The results show that the luciferase activity of the wild-type (WT) 3′ UTR-TET1 significantly decreased in the cells transfected with the miR-30a mimic, whereas the miR-30a mimic could not inhibit the luciferase activities of the mutant-type (MT) 3′ UTR-TET1. The data suggest that TET1may be a miR-30a target.
To confirmTET1 as a target gene of miR-30a, we used cell transfection with miR-30a mimic or inhibitor to identify the relationship. The results show that the TET1 expression levels increased in the H2O2-treated group compared with that in the control group, whereas the miR-30a mimic could inhibit the TET1 expression and the miR-30a inhibitor could improve the TET1 expression. The data further confirm that TET1 is a target gene of miR-30a.
Interference on TET1 inhibited hydroxymethlation of Drp-1 promoter 6 of 25
Our previous study showed that miR-30a could block the apoptosis of pulmonary epithelial cells by repressing mitochondrial fission, which is dependent on Drp-1.
However, the regulatory mode between TET1 and Drp-1 is not clear. We further explored the regulated pattern between TET1 and Drp-1. We designed three specific primers for the predicted methylation sites in the Drp-1 promoter region and interference on TET1 ( 
miR-30a as a potential therapeutic target for IPF
To explore whether miR-30a can act as a potential therapeutic in vivo, we synthesized a miR-30a agomir and sprayed it across the mouse lung using a Penn-Century MicroSprayer (Penn-Century Inc., Wyndmoor, USA). The fibrosis and the collagen content were evaluated using hematoxylin and eosin (H&E) and Masson's staining. The results show that the mice in the miR-30a agomir group presented a more continuous structure with a better intact wall of bronchial mucous membrane than the BLM group. The alveoli in the miR-30a agomir group showed clearer hollow cavities with thinner alveolar walls than the BLM group. In addition, 7 of 25 the lung mesenchyme in the agomir group showed fewer collagen fibers, indicating that the hallmark of the fibroblastic foci decreased distinctly decreased. These findings suggest that miR-30a agomir could improve pulmonary fibrosis. The miR-30a level decreased significantly and TET1 increased significantly in the BLM group compared with those in the sham group, and miR-30a agomir could improve the miR-30a expression and inhibit the TET1 expression in the agomir group compared with those in the BLM group.
To further investigate the anti-fibrosis action of miR-30a agomir in vivo, we tested the expression levels of hydroxyproline (HYP), a-SMA, E-cadherin, and vimentin, which are indicators of pulmonary fibrosis, after spraying with miR-30a agomir in vivo. The results demonstrate that agomir could reduce the HYP content, a-SMA, and vimentin expression compared with those in the BLM group but improved the E-cadherin expression.
Discussion
Currently, IPF is the most life-threatening idiopathic disease, presenting a mortality rate that exceeds those of numerous cancers [10, 13] . Although several genetic, epigenetic, and proteomic studies have been conducted to date, studies investigating miRNA regulatory networks in IPF have only recently gained significant attention [2] . Our previous study revealed that miR-30a can block mitochondrial fission, which is dependent on Drp-1, to regulate the development of IPF. However, the regulatory mechanism between miR-30a and Drp-1 has yet to be investigated. BCL6 [18] , p53 [19] , and RUNX2 [20] . In the present study, we identified and validated TET1 as a target of miR-30a and the regulatory mode between TET1 and Drp-1. Furthermore, we demonstrated that miR-30a could act as a potential therapeutic by targeting TET1 through regulating the hydroxymethlation of Drp-1 promoter in IPF.
The TET protein family includes three members (TET1-3), all of which are capable of converting 5-methylcytosine to 5-hydroxymethylcytosine (5-hmC) in a 2-oxoglutarate-and Fe(II)-dependent manner [21, 22] . In addition, the DNA methylation at the 5-position of cytosine is a key epigenetic mark, which is critical for various biological and pathological processes [23, 24] . Genome-wide studies demonstrated the enrichment of 5-hmC at the enhancers, promoters, and gene bodies of actively expressed genes [25, 26] . The presence of 5-hmC may contribute to both passive and passive DNA demethylation. TET1 is required to maintain the normal abundance and distribution of 5-hmC, which prevents the hypermethylation of DNA and promotes the demethylation of DNA by a sequential process involving the deamination of 5-hmC to 5-hmU; moreover, TET1 is required for the regulation of genes-encoding molecules involved in chromosome maintenance and DNA repair [27] . TET1 expression is the highest in long-term hematopoietic stem cells, multipotent progenitors, common lymphoid progenitors, and common myeloid progenitors, and decreases during B lineage commitment and becomes undetectable in immature and mature myeloid cells. The loss of TET1 function predisposes HSCs to malignancy and, more specifically, B cell lymphoma [28] . In drug addiction, TET1
normally regulates cocaine reward negatively, and the cocaine-induced suppression of TET1 in nucleus accumbens contributes to enhanced drug sensitivity [29] . This epigenetic lesion has also been extended to the DNA methylation-mediated silencing of miRNA [30] [31] [32] . miR-22 was recently found to exert its metastatic potential by silencing antimetastatic miR-200 through the direct targeting of the TET family of methycytosine dioxygenases, thereby inhibiting the demethylation of the miR-200
promoter [33] . However, the mechanism by which this epigenetic mark of 5-hmC and the related enzyme of TET participate in IPF progression remains unknown. Our data illustrate that the decrease in the5-hmC of Drp-1 was caused, at least in part, by the decreased expression level of the key enzyme TET1, which controls the 5-hmC production.
Several recent studies indicated that miR-30a performs critical roles in various biological processes. For example, the expression of Ubc9 is regulated by miRNA-30a in human subcutaneous adipocytes [34] . miR-30a reduces IRF4 expression through the specific binding with the 3′ UTR, thus suppressing theTh17 differentiation and preventing the full development of autoimmune encephalomyelitis [35] . miR-30a targets the DNA replication protein RPA1, hinders the replication of DNA, and induces DNA fragmentation [36] . These studies lack information on the therapeutic effect of miR-30a in vivo. Moreover, pulmonary fibrosis data have yet to be reported. To verify the therapeutic effect of miR-30a further, the miR-30a agomir was designed and applied in vivo. Here, we found that injection of miR-30a agomir to overexpressed miR-30a leads to thinner walls of alveoli and fewer fibers, which could speed up the diffusion of oxygen into the adjacent blood capillaries and the opposite movement of carbon dioxidecompared with the BLM group.
In addition, we assessed the significance of circulating miR-30a in clinical application. Future studies need to expand the analysis of miR-30a to a larger cohort of patients with IPF to determine with statistical confidence whether reduced miR-30a expression levels are correlated with poor patient outcome. In summary, our findings in vivo and in vitro together with the clinical data of patients with IPF provide evidence that the upregulation of miR-30a could downregulate the expression level of its target gene TET1 and exert anti-fibrotic effect and protection function against pulmonary injury. Our work suggests a novel approach to prevent pulmonary fibrosis damage and provides a potential therapeutic target for pulmonary fibrosis treatment.
Materials and methods
IPF patients
IPF was diagnosed in accordance with the American Thoracic Society/European
Respiratory Society consensus criteria [1] , which include clinical, radiographic, and characteristic histopathological features (n=40). 5 mL of blood sample was obtained from each participant and prepared for testing. Matched plasma samples from healthy volunteers (n=40) were selected corresponding to the IPF patients' sex and age. As stated in the agreement, a written informed consent was obtained by the doctors from each participant. The ethics committee of Binzhou Medical University approved this study.
Cell transfection
A549 cell lines were purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). Cell culture was as our previously described [37, 38] .
miR-30a mimic, inhibitor and TET1 siRNA were synthesized by RiboBio Co. Ltd 
Quantitative real-time PCR (qRT-PCR)
Total RNA was isolated using TRIzol reagent. RNA quantity and quality were measured using the NanoDrop 2000 spectrophotometer (Thermo Scientific, USA) and RNA integrity was assessed by standard denaturing agarose gel electrophoresis. 
Dual luciferase assays
The wild type and mutation type 3'UTR of TET1 containing miR-30a-binding site were synthesized by Obio Technology Co., Ltd (Shanghai, China). 293T cells were plated at 50~60% confluence and transfected with miR-30 mimics as well as the 3'UTR luciferase vector using Lipofectamine™ 3000 transfection reagent according to the manufacturer's instructions. Forty eight hours after transfection, luciferase assay was performed using dual luciferase reporter assay kit in compliance to the manufacturer's instructions.
H&E and Masson's Trichrome staining
Pulmonary tissues were fixed by inflation with 4% paraformaldehyde overnight, dehydrated in 70% ethanol, and embedded in paraffin wax. Sections of 4 mm thickness were prepared and stained with H&E or Masson's trichrome staining according to the manufacturer's standard protocol. Degrees of microscopic interstitial fibrosis and collagen were graded as our previously described [39] .
Western blot analysis
Protein concentration was quantified using a bicinchoninic acid protein assay kit and boiled with the sample buffer in a water bath for 5 min. Protein samples were separated with 15% SDS-PAGE gels for 2 hours and transferred onto a polyvinylidene difluoride membrane, which was subsequently blocked in 5% non-fat milk for 2 hours.
Blots were probed using the primary antibodies. The anti-Drp1 antibody was from Santa Cruz Biotechnology. After three times washing with tris buffered saline tween, the horseradish peroxidase-conjugated secondary antibodies were added.
Antigen-antibody complexes were visualized by enhanced chemiluminescence.
Statistical analysis
Data were expressed as the mean ± SD from the indicated number of independent experiments. Statistical analysis was performed with SPSS 17.0 software by one-way ANOVA and Student's t-test. P < 0.05 was considered to indicate a statistically significant difference. 
